Advancements in chimeric antigen receptor engineered T-cell (CAR-T) therapy have
revolutionized treatment for several cancer types over the past decade. Despite this success …

Chimeric antigen receptor (CAR) NK and T cell therapy are promising immunotherapeutic
approaches for the treatment of cancer. However, the efficacy of CAR NK/T cell therapy is …

Today, adoptive cell therapy has many successes in cancer therapy, and this subject is
brilliant in using chimeric antigen receptor T cells. The CAR T cell therapy, with its FDA …

Adoptive T‐cell transfer (ACT) therapies, including of tumor infiltrating lymphocytes (TILs)
and T cells gene‐modified to express either a T cell receptor (TCR) or a chimeric antigen …

The search for innovative anti-cancer drugs remains a challenge. Over the past three
decades, antibodies have emerged as an essential asset in successful cancer therapy. The …

Background Commercial anti-CD19 chimeric antigen receptor T-cell therapies (CART19)
are efficacious against advanced B-cell non-Hodgkin lymphoma (NHL); however, most …

Chimeric antigen receptor (CAR)-T cell therapy for solid tumors faces significant hurdles,
including T-cell inhibition mediated by the PD-1/PD-L1 axis. The effects of disrupting this …

Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful
personalized therapeutic agents showing dramatic preclinical and clinical results …

The use of T cells expressing chimeric antigen receptors (CARs) that can target and
eliminate cancer cells has revolutionized the treatment of B‐cell malignancies. In contrast …

Chimeric antigen receptor (CAR) T therapies hold immense promise to revolutionize cancer
treatment. Nevertheless, key challenges, primarily in solid tumor settings, continue to hinder …